Sanofi/Regeneron eye 2017 EU approval for Humira-beater sarilumab

Sanofi's headquarters in Paris
Regeneron HQ

Sanofi ($SNY) and R&D partner Regeneron ($REGN) could have their experimental IL-6 inhibitor sarilumab approved in Europe by early 2017.

The French Big Pharma and the U.S. biotech said the European Medicines Agency has today accepted for review their marketing app for sarilumab--an IL-6 inhibitor mAb that wants a blockbuster license for rheumatoid arthritis (RA).

The drug is already on the FDA’s books, with the U.S. regulator set to make a decision on whether to approve the med by the end of October.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

Things are looking good for the pair--which have been ramping up the R&D deals between them over the past two years--as sarilumab recently bested AbbVie's ($ABBV) top-selling autoimmune TNF blocker Humira (adalimumab) in a Phase III head-to-head study in RA.

Humira, the biggest-selling med in the world, made around $14 billion last year and has a host of licenses including rheumatoid arthritis, moderate to severe plaque psoriasis, psoriatic arthritis and others.

The drug is, however, set to see its sales hit in the coming years with a slew of cheaper biosimilars waiting in the wings to usurp its top-selling drug spot.

Sarilumab would become the second approved product to come out of from Sanofi's wide-ranging partnership with Regeneron, following on from its launch of Praluent (alirocumab), an antibody designed to clear out bad cholesterol by blocking a protein called PCSK9.

- check out the release

Related Articles:
Regeneron's arthritis drug aces Phase III with the FDA in sight
Sanofi and Regeneron line up for FDA approval with an arthritis treatment

Suggested Articles

Flagship Pioneering has raised $824 million for a fund to support biotech and health companies that have come up through its Flagship Labs foundry.

The FDA’s warning letters to breast implant manufacturers come during newly galvanized agency probes into the long-term safety of silicone implants.

At the annual meeting of the American College of Cardiology this week, a new analysis of Merck’s anacetrapib cast a shadow on DalCor’s hypothesis